Villaris Therapeutics

What Villaris Therapeutics does

Villaris Therapeutics was a preclinical-stage biopharmaceutical company founded in 2019 and headquartered in Cary, North Carolina. The company focused on the discovery and development of therapeutic candidates targeting dermatology, inflammation, and hematologic indications. At the time of acquisition, Villaris operated with a lean team of 1-10 employees and had not advanced any product to commercial or clinical-stage milestones disclosed in the source material.

As a preclinical entity, Villaris had no commercial revenue and no disclosed pricing or go-to-market model. Its business model was centered on R&D-driven value creation, with the underlying technology and pipeline assets representing the company's principal economic value. The source material does not disclose specific therapeutic modalities, lead candidates, platform technologies, or scientific founders.

In 2025, Villaris was acquired by Incyte Corporation (NASDAQ: INCY) for approximately $1.4 billion. The transaction was driven by Incyte's portfolio diversification strategy, intended to reduce reliance on the Jakafi franchise and broaden Incyte's pipeline into dermatology and inflammatory diseases. Following the acquisition, Villaris no longer operates as an independent entity and has been integrated as a wholly-owned subsidiary of Incyte.

Name

Villaris Therapeutics

Website

https://villaristherapeutics.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

1–10 employees

Short description

Villaris Therapeutics is a preclinical-stage biopharmaceutical company developing therapies for dermatology, inflammation, and hematologic indications. Founded in 2019 and based in Cary, North Carolina, the company was acquired by Incyte Corporation in 2025 for approximately $1.4 billion.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Biopharmaceutical development
• Inflammatory disease therapies
• Dermatology therapeutics
• Preclinical drug development
• Antibody therapeutics

Headquarters

HQ city

Cary

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

Villaris Therapeutics is a preclinical-stage biopharmaceutical company developing therapeutic candidates for dermatology, inflammation, and hematologic indications. The company's pipeline is focused on novel antibody-based approaches to address immune-mediated skin and inflammatory diseases, positioning it as a research-driven pipeline asset for larger biopharma acquirers.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves1 record

Expansion highlights2 records

Direct peers

• Dermavant Sciences: Specialty dermatology biopharmaceutical company focused on inflammatory skin diseases. Comparable as a mid-stage dermatology-focused biotech that was similarly acquired (by Organon) for pipeline value, mirroring Villaris's acquisition profile.
• Arcutis Biotherapeutics: Late-stage dermatology biopharma developing topical treatments for inflammatory skin conditions. Direct peer in dermatology/inflammation with overlapping therapeutic targets and similar indication focus.
• Aclaris Therapeutics: Clinical-stage dermatology biopharmaceutical company developing therapies for immuno-inflammatory skin diseases. Comparable as a small-cap, dermatology-focused biotech with similar indication focus and company size profile.
• TopiVert: Preclinical/early clinical-stage company developing narrow-spectrum kinase inhibitors for inflammatory skin diseases. Closely comparable as a dermatology/inflammation-focused preclinical biotech that was acquired for pipeline value.

Emerging players

• AnaptysBio: Clinical-stage immunology company developing inflammation and immuno-oncology antibodies. Comparable as a small-cap biotech with inflammation focus and similar pipeline-stage risk profile to Villaris.

Broad incumbents

• Arena Pharmaceuticals: Immunology/inflammation-focused biopharma (etrasimod, ralinepag) acquired by Pfizer for ~$6.7B. Comparable as an inflammation-focused biotech that was acquired by a large pharma for pipeline diversification, similar strategic exit profile to Villaris's acquisition by Incyte.
• Kadmon Holdings: Small-molecule-focused biopharma developing therapies for inflammatory and fibrotic diseases, acquired by Sanofi for ~$1.9B. Comparable transaction archetype: small inflammation-focused biotech acquired by large pharma for portfolio diversification.
• Incyte Corporation: Acquirer of Villaris; large biopharma with established dermatology, inflammation, and hematology franchises (Jakafi, Opzelura). Relevant as the integration vehicle now driving Villaris's pipeline and as the broader context for the acquisition thesis.
• Pfizer: Major biopharma with significant dermatology/inflammation commercial presence (Cibinqo, Eucrisa). Relevant as a large incumbent competing in the same dermatology/inflammation space Villaris's assets target.
• AbbVie: Major biopharma with industry-leading dermatology/inflammation franchises (Skyrizi, Rinvoq, Humira legacy). Sets the competitive bar Villaris's assets must clear and represents the dominant incumbent in Villaris's target indications.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/villaris-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Villaris Therapeutics